Intellia develops CRISPR gene editing treatments for severe diseases, with lead candidates in late stage clinical trials. It last closed at $10.00 on Nov 20, up 5.04% on the day. The next earnings report for NTLA is expected around Thu, Feb 25, 2027. For the quarter ended Sep 2026, NTLA reported EPS of -$0.91 on revenue of $7.2M, with revenue down 48.0% from a year ago. Over its last 8 reports the stock moved an average of 7.2% the session after earnings. Over the last 12 months NTLA insiders bought $1.4M of stock on the open market and sold $2.3M, according to SEC Form 4 filings.
AI Auto Pilots
Is NTLA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold NTLA.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on NTLAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
NTLA · as of the Nov 20 close · updated each morning
Downtrend
The stock is 12% below its 20 day and 17% below its 50 day average. It is 29% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 41). The nearest support is the Pivot at $9.90, and the nearest resistance the Pivot R1 at $10.50.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 8.5%/day
Key levels
$18.4852 week high+84.8%
$12.89200 day average+28.9%
$12.11100 day average+21.1%
$11.99Swing high (Oct 20)+19.9%
$11.6750 day average+16.7%
$11.2420 day average+12.4%
$10.50Pivot R1+5.0%
$10.00Last close
$9.90Pivot−1.0%
$9.40Pivot S1−6.0%
$7.9552 week low−20.5%
Indicators
RSI (14)
40.74
Middle of its range
Neutral
MACD
-0.60
Below its signal line
Bearish
Stochastic
14.2
Near the bottom of its range
Oversold
ADX (14)
15.4
No clear trend
Williams %R
-73.1
Oversold below −80, overbought above −20
Neutral
CCI (20)
-102.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−11.9%
Change over 10 sessions
Bearish
ATR (14)
$0.85
Typical daily range, 8.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 19.3%/day
Key levels
$18.4852 week high+84.8%
$12.89200 day average+28.9%
$12.11100 day average+21.1%
$11.99Swing high (Oct 20)+19.9%
$11.6750 day average+16.7%
$11.2420 day average+12.4%
$10.50Pivot R1+5.0%
$10.00Last close
$9.90Pivot−1.0%
$9.40Pivot S1−6.0%
$7.9552 week low−20.5%
Indicators
RSI (14)
41.38
Middle of its range
Neutral
MACD
-0.62
Below its signal line
Bearish
Stochastic
15.6
Near the bottom of its range
Oversold
ADX (14)
10.9
No clear trend
Williams %R
-80.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-185.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−14.8%
Change over 10 sessions
Bearish
ATR (14)
$1.93
Typical daily range, 19.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NTLA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how NTLA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow NTLA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for NTLAHow many large options trades hit NTLA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in NTLA in the last 90 days.
From SEC Form 4 filings by NTLA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NTLA is in one of them and how their past NTLA trades turned out.
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About Intellia Therapeutics
Intellia is a biopharmaceutical company based in Cambridge, Massachusetts, that develops treatments using CRISPR gene editing. Its lead candidates are designed to address the underlying cause of rare, severe diseases, including hereditary angioedema and ATTR amyloidosis, and are given as a single intravenous infusion. The company's lead candidates are in late stage clinical trials, and it is preparing for possible commercial launches aimed at patients with these conditions. It also works with partners, such as Regeneron, on additional programs.